

Building Confidence to Build Immunity: Vaccine Hesitancy and COVID-19

Friday, January 29, 2021

Join us online!



@AllHealthPolicy




Alliance for Health Policy



@AllianceforHealthPolicy

#AllHealthLive






Sponsors







Participating in the Webinar





Panelists



Reed Tuckson, M.D., FACP Managing Director, Tuckson Health Connections; Board Chair, Alliance for Health Policy



@DrReedTuckson



Heidi Larson, Ph.D.

Professor of Anthropology, Risk and
Decision Science; Director, The Vaccine
Confidence Project, London School of
Hygiene & Tropical Medicine



@ProfHeidiLarson



Hemi Tewarson, MPH, J.D. Visiting Senior Policy Fellow, Duke-Margolis Center for Health Policy



@hemitewarson



Moderator

Rachel Nuzum, MPH
Vice President, Federal and State Health
Policy, The Commonwealth Fund



@raenuzum







Hemi Tewarson, MPH, J.D.

Visiting Senior Policy Fellow,
Duke-Margolis Center for Health Policy



Building Confidence to Build Immunity: Vaccine Hesitancy and COVID-19

January 29, 2021


Hemi Tewarson, Visiting Senior Policy Fellow, Duke-Margolis Center for Health Policy





Subscribe to our monthly newsletter at dukemargolis@duke.edu

Variability in Doses Administered Across States



- U.S. Vaccination Campaign
 - Doses administered: 25,646,032
 - Population given 2nd dose: 1.2%
 - Daily rate of doses administered: 1,209,969
- High variability in % of doses administered across states:
 - Supply used (nationally): 54.3%
 - North Dakota currently highest performing for doses administered
 - Lowest performing states reporting ~45% doses administered
- States report discrepancies between CDC reported data and internal data



Vaccine Distribution: Key Themes and Challenges Across States

Vaccine Supply and Transparency

Slow rollout of Federal LTCF Partnership Variable Public Health Infrastructure

Communication and Hesitancy

Managing
Public and
Media Pressure

Technology for Scheduling

Data Reporting

Vaccine Distribution: Speed vs. Equity

Political and public pressure to speed up vaccine delivery but how to balance equity Early data shows significant disparities among the 17 states reporting data by race

Challenges are hesitancy combined with access for communities of color

Various strategies include set aside % for vulnerable communities, locating sites in easily accessible locations, education and communication

Potential crisis point in the future if/when all who want to be vaccinated are already vaccinated and relationships have not been built with harder-to-reach communities

Contact

Hemi Tewarson
Visiting Senior Policy Fellow
Duke-Margolis Center for Health Policy
hemi.tewarson@duke.edu

Thank you!





Heidi Larson, Ph.D

Professor of Anthropology, Risk and Decision Science; Director, The Vaccine Confidence Project, London School of Hygiene & Tropical Medicine





State of Vaccine Confidence in a time of COVID-19

Heidi J Larson

Professor of Anthropology, Risk and Decision Science


Director, The Vaccine Confidence Project





Global attitudes to vaccination vary considerably

Share of population in 2019 who strongly agree that vaccines are safe/effective (%)



Graphic: Alan Smith

Source: Figueiredo, Simas, Karafillakis, Paterson and Larson in The January (2020)

© FT


COVID-13 Collidelice globally

111 y (December 2020)

d? დ

CONFIDENCE PROJECT


When a vaccine for the coronavirus becomes available, will you get vaccinated?



Lebanon 42.6 Pakistan 31.8 33.7 27.9 30.1 21.2 Paraguay Serbia 27.8 10.2 23.9 13.3 France 22.5 Croatia 13.0 Poland 21.0 19.5 26.8 37.4 Nigeria Slovenia 20.0 16.4 Germany 15.9 32.0 USA 35.9 29.8 14.0 Chile 34.4 13.9 Argentina 13.0 11.9 35.9 Peru 37.5 33.4 Ireland 11.4 Spain 11.3 Italy 10.4 33.2 44.5 Canada 8.8 Ecuador 8.8 UK 8.4 47.7 Mexico 7.8 52.9 Brazil 7.8 54.1 Finland 40.6 5.3 Hong Kong 5.3 25.0 20.7 Japan 4.3 Malaysia 40.1 Indonesia India 32.9 57.8 43.1 Denmark South Korea 31.8 China 47.3 Vietnam 69.2 25 50 75 100 0

percentage (%)

determinants of intent to acept a COVID-19 vaccine (fixed-effects)







Reed Tuckson, M.D., FACP

Managing Director, Tuckson Health Connections; Board Chair, Alliance for Health Policy



Learn More

Additional resources available online »

- Full speaker bios
- Resource list
- Expert list
- Presentation slides
- Recording

www.allhealthpolicy.org



We value your input!

Please fill out the evaluation survey you will receive immediately after this presentation, or via email this afternoon!



www.allhealthpolicy.org





Thank you for attending.